Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) reported real‑world data showing the Shield blood-based colorectal cancer screening test had 95% adherence in the first 20,000 patients with clinical orders from May 2022–June 2024. Shield is the first blood test with FDA approval as a primary screening option for average‑risk adults aged 45+. Median turnaround time was 15 days from sample receipt to report.
An additional Appalachian clinic analysis showed screening rates rose from 45% to 90% after Shield was offered and a 98.5% adherence rate. Shield is covered by Medicare and the VA Community Care Network and is commercially available across the U.S.
Guardant Health (Nasdaq: GH) priced an upsized private offering of $350.0 million aggregate principal amount of 0% convertible senior notes due May 15, 2033, with settlement expected on November 7, 2025. The initial purchasers have a 13-day option to buy an additional $52.5 million of notes. The notes bear no regular interest, are senior unsecured, and convert at an initial rate of 8.2305 shares per $1,000 principal (initial conversion price ~$121.50), a ~35% premium to the concurrent public offering price.
Guardant also priced a concurrent underwritten public offering of 3,333,333 shares at $90.00 per share (gross proceeds ~$300.0 million), with a 30-day option to buy up to 499,999 additional shares. Estimated net proceeds from the notes are ~$339.1 million (or ~$390.0 million if the option is exercised). Proceeds are intended for general corporate purposes, which may include repurchasing certain 2027 notes.
Guardant Health (Nasdaq: GH) priced an upsized underwritten public offering of 3,333,333 shares of common stock at $90.00 per share, up from a previously announced $250.0 million size. The company granted underwriters an option for an additional 499,999 shares. The offering is expected to close on November 7, 2025, subject to customary closing conditions.
Guardant estimates net proceeds of approximately $284.4 million (excluding any option exercise). Concurrently, Guardant priced an upsized convertible notes offering of $350.0 million principal amount due 2033, with an option for an additional $52.5 million. Proceeds are planned for general corporate purposes and may include repurchasing a portion of its 0% convertible senior notes due 2027, though no repurchase agreement is in place.
Guardant Health (Nasdaq: GH) announced a proposed underwritten public offering of $250.0 million of common stock and a 30‑day option for underwriters to buy up to an additional $37.5 million of shares. Guardant Health also announced a concurrent proposed offering of $300.0 million aggregate principal amount of convertible senior notes due 2033, with an initial purchaser option to buy up to an additional $45.0 million of notes.
Both offerings are subject to market and other conditions, are not contingent on each other, and will be made by prospectus supplement under a shelf registration. Net proceeds are intended for general corporate purposes and may include repurchasing a portion of the company’s 0% convertible senior notes due 2027, although no repurchase is assured.
Guardant Health (Nasdaq: GH) announced a proposed private offering of $300.0 million aggregate principal amount of convertible senior notes due May 15, 2033, with an initial purchaser option to buy up to an additional $45.0 million. The notes will be senior, unsecured, accrue interest semi‑annually, and will not be redeemable at GH’s election before November 20, 2029. Conversion may be settled in cash, shares or a combination at GH’s election.
Concurrently, GH intends to offer $250.0 million of common stock, with a 30‑day underwriter option for $37.5 million. Net proceeds are intended for general corporate purposes, which may include repurchasing a portion of GH’s 0% convertible senior notes due 2027, subject to market conditions and no assurances of completion.
Guardant Health (Nasdaq: GH) reported Q3 2025 revenue of $265.2M, up 39% YoY, driven by Oncology, Screening, and Biopharma & Data. The company raised full‑year 2025 revenue guidance to $965–$970M (≈31% growth) and now expects Screening revenue of $71–$73M from ~80,000–82,000 Shield tests. Q3 non‑GAAP gross margin was 66%. Q3 net loss narrowed to $92.7M and non‑GAAP net loss was $48.3M. Cash and equivalents were $689.5M. Management cited expanded Shield MCD, new partnerships, Guardant360 PMA submission, and FDA companion diagnostic approvals as key operational milestones.
Guardant Health (Nasdaq: GH) and Zephyr AI announced a strategic partnership on October 27, 2025 to combine multimodal molecular and clinical real-world data with AI/ML to identify novel cancer biomarkers, predict targeted therapy response, and support biopharma drug development.
The collaboration will integrate Zephyr AI’s analytics with Guardant’s Infinity AI capabilities to generate biologically interpretable, real-world‑validated predictions for therapy selection and response monitoring, aimed at accelerating precision oncology research and enabling actionable insights for oncologists and developers.
Guardant Health (Nasdaq: GH) will present data at ACG 2025 showing blood-based testing can boost cancer screening adherence. An expanded cohort of 20,000 patients confirmed Shield delivered an adherence rate of over 90% for colorectal cancer screening, versus typical overall CRC screening adherence of 28–71%. Shield is the first and only FDA-approved blood test as a primary screening option for average-risk adults aged 45 and older. A separate Cedars Sinai-led survey of >1,700 US adults found 43.9% of screening-eligible individuals prefer a blood test for colorectal and lung cancer versus traditional methods. Guardant and collaborators will present multiple abstracts and posters at ACG 2025 in Phoenix, Oct 24–29, 2025.
Guardant Health (Nasdaq: GH) will present 15 abstracts at the ESMO Congress 2025 in Berlin, Oct 17–21, covering work across the cancer care continuum.
Presentations showcase blood-based assays for MRD detection, recurrence monitoring, tumor profiling, and therapy response across multiple tumor types including lung, colorectal, breast, head and neck, and cancers of unknown primary. Key technologies highlighted include Guardant Reveal, Guardant360, and Guardant Infinity with data from studies such as CROWN, PEGASUS, PRECISION, SIBYL, CUPIDO, and others.
Selected topics: molecular lung subtyping, FGFR alteration landscapes in NSCLC, ctDNA-guided adjuvant decisions in colorectal cancer, and ctDNA monitoring after chemoradiation in head and neck cancers.
Guardant Health (Nasdaq: GH) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Company management will host a webcasted conference call starting at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company’s Investors website at www.guardanthealth.com. The webcast will be archived and available for replay after the event.